USNA

Usana Health Sciences Inc

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert Fuller sold 1,058 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $17.00, for a total transaction of $17,986.00. The transaction was disclosed in a filing...

EHC is expanding its inpatient rehab network and posting steady revenue and cash-flow growth, but Medicaid policy risks and higher debt remain concerns.

J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.

CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.

Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.

Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.

USNA vs. ZTS: Which Stock Is the Better Value Option?

Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.

USANA Health (USNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.